Clinical Trial

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-06-04
Trial Details
NCT Number NCT07611552
Lead Sponsor Huazhong University of Science and Technology
Conditions Obesity & Overweight
Enrollment 600 participants
Start Date 2026-06
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-03